Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

Revive Therapeutics Ltd. C.RVV

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

Latest News

This life sciences company is gearing up to treat long COVID


Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of...


Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product


Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder


Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of...


Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID


Revive Therapeutics Provides Corporate Update


Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private...


Revive Therapeutics Explores the Use of Bucillamine for Long COVID


Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for...


Revive Therapeutics Ltd. Announces Offering of Up to $3 Million


Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence...


Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of...


Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders


Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial...



Opinion

Opinion

A Potential Psychedelic and COVID Therapy Play…All in One Stock


Micro-Cap Pharma Moving Ahead with Plans for Phase 3 US Trial of a Repurposed Drug for Covid-19


WeedMD Gives 18 Cent Cannabis Researcher RVV, a Fighting Chance


Updates on DVI, CCC and RVV


RVV Comps / Ikkuma (oil & gas) Intro at .52


Micron Trades This Week & RVV’s MMJ Science


RVV.v: ZYNE.Q an ideal Valuation Comparable


16 Cent RVV the Leader in Cannabinoid Research for Liver Disease


19 Cent RVV Could Have Windfall Gain Potential


Seasonal Weakness / Dropping DBL / RVV Update


RVV Update and DXD Intro


Merus 3mth 60% Gain on $342M Takeover


27 Cent RVV: Comps Show Fair Value 40 to 80 Cents


April Caution / RVV .24 World Class Advisors


April Caution / DVI 660% / RVV